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Synopsis/Precis 
Childhood uveitis comprises a heterogenous group of rare, blinding eye diseases. High-level 
evidence to support practice is lacking. We report evidence of absence of consensus, amongst 
UK specialists, on the management of childhood anterior uveitis. 
35/35 
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ABSTRACT  
Background/Aims 
There is a paucity of high-level evidence to support the management of childhood uveitis, 
particularly for those children without juvenile idiopathic arthritis uveitis (JIA). We 
undertook a modified Delphi consensus exercise to identify agreement in the management of 
chronic anterior uveitis (CAU), the most common manifestation of childhood disease.  
Methods  
A four round, two panel, process was undertaken between June and December 2017. 
Paediatric uveitis specialists identified through multiple sources, including a multicentre 
network (the Paediatric Ocular Inflammation Group, POIG), were invited to participate. They 
were asked whether they agreed with items derived from existing guidelines on the 
management of JIA-uveitis when extrapolated to the population of all children with CAU. 
Consensus was defined as agreement greater than or equal to 75% of respondents. 
Results 
26 of the 38 (68%) invited specialists participated with the exercise, and response rates were 
100% for rounds one to three, and 92% for round four.  Consensus was reached on 23 of the 
44 items. Items for which consensus was not reached included management at presentation, 
use of systemic and periocular steroids for children with severe disease, and the role of 
conventional steroid sparing immunosuppressants beyond methotrexate. 
Conclusion 
The areas of management uncertainty at the level of the group, as indicated by absence of 
consensus, reflect the areas where the evidence base is particularly poor. Our findings 
identify the key areas for the future research needed to ensure better outcomes for this 
blinding childhood ocular inflammatory disorders.  
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INTRODUCTION 
Paediatric uveitis, a group of rare inflammatory eye disorders, affects approximately 2-3 per 
10,000 children.1,2 The majority of childhood uveitis is chronic anterior uveitis (CAU).1,3 
Juvenile idiopathic arthritis (JIA), an umbrella term for a group of childhood arthropathies, is 
the most frequent systemic disorder accompanying CAU.2,4,5 However, up to 40% of children 
with chronic anterior uveitis never develop JIA.3   Prolonged uveitis activity may cause 
irreversible structural damage, and there is a risk of severe visual impairment in at least one 
eye before adulthood.6,7 Individuals remain at risk of further visual loss in adulthood.8,9 
Management of childhood uveitis is complicated by the heterogeneity of the underlying 
systemic disorders, and uncertainties regarding disease natural history and the likely variation 
in underlying endophenotype.1,3,7 Whilst novel therapies have emerged, the lack of molecular 
understanding and the rarity of the associated systemic disorders associated with childhood 
uveitis further complicates management by limiting the generalisability of the existing 
evidence. Up to a quarter of children with JIA associated uveitis (JIA-U) do not achieve 
disease control with adalimumab.10 11 Moreover, high level comparative therapeutic research 
for other forms of paediatric uveitis is lacking.  
The Delphi consensus method is a structured iterative process used to elicit or determine 
consensus from a defined expert opinion group when high level evidence is lacking.12 The 
traditional Delphi approach uses the expert group to develop item lists. A common 
modification is the evidence based pre-selection of  items for which consensus is sought, 
where such evidence is “available and useable”.12 In 2017, the Paediatric Ocular 
Inflammation Group (POIG, n=63 specialists) was established as a national multidisciplinary 
collaborative clinical research network which aimed to improve the evidence base for 
children with inflammatory eye disease. Within POIG sit disorder-specific groups of 
clinicians, the largest of which is the uveitis subgroup. We report the findings of a modified 
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Delphi approach, undertaken through the POIG Uveitis Group, which aimed to identify areas 
of national consensus in the management of childhood chronic anterior uveitis.   
 
MATERIALS AND METHODS 
We undertook a four round modified Delphi process between June and December 2017, 
involving two specialist panels (fig 1) selected on the basis of the following criteria:  
Panel one:  Paediatric Ophthalmologists or Uveitis Specialists managing uveitis in children 
(individuals aged under 18 years) within UK specialist regional centres. Within the UK, anti-
TNF alpha immunomodulation treatments are commissioned and funded by NHS England 
through designated specialist regional centres.  These centres were also the recruiting centres 
for the SYCAMORE study10 and have particular experience in the management of complex 
or refractory childhood uveitis.  
Panel two: Consultant Paediatric Ophthalmologists or Uveitis Specialists managing uveitis in 
children at other UK tertiary care centres. Tertiary care centres were identified through POIG 
membership and via membership lists for two existing national paediatric ophthalmology 
clinical collaborative research networks (the British Childhood Visual Impairment and 
Blindness Study Group, and the British Isles Congenital Cataract Interest Group).13 
Panel members were asked to agree or disagree with items derived from existing international 
guidelines on the management of JIA-U. These comprised, firstly, interdisciplinary 
guidelines developed by the German Ophthalmological Society and based on a systematic 
review of the available evidence undertaken in 2009.14 Secondly, a survey undertaken in 
2013 through an international network of uveitis specialists.15 Thirdly, the treatment 
algorithm within the SYCAMORE randomised controlled trial, which were based on a 
systematic review of the evidence and a multi-centre consensus process undertaken in 2013.10 
Lastly, a management algorithm developed in 2013 by a national interdisciplinary panel of 
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European specialists.16 The items selected for this consensus exercise was limited to those 
within these four papers, with, for example, absence of items on investigation of infectious 
uveitis, or use of intravitreal drugs.  
The items within the guidelines were circulated amongst the core group (ALS, CE, JSR, AR, 
ADD) for refinement, specifically removal of duplicate items and clarification of item 
wording, and examination of consistency with the existing evidence from randomised 
controlled trials in childhood uveitis, as identified through a concurrent systematic review of 
childhood uveitis studies within the International Committee of Medical Journal Editors 
Clinical Trials Registration system.17 There were 44 items extracted (Supplemental file).  
The items were distributed to the panels with accompanying item metadata (links to the 
originating literature, and the Oxford Centre of Evidence Based Medicine (OCEBM) level of 
the relevant supporting evidence for each item as cited in the originating guideline literature). 
Panel members were invited to use an electronic survey form (SurveyMonkey®) to state 
whether they agreed or disagreed with each item (figure 1). Summated responses (percentage 
of agreement and anonymised collated free text comments) were redistributed to the group as 
described in figure 1. For each round, panel members were given six weeks to reply, with a 
reminder email sent four weeks after initial contact.  
Analysis  
Consensus was reached when at least 75% of respondents agreed, or disagreed with an item.   
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RESULTS 
Of the 15 specialists invited to join panel one, 12 (80%) replied. These comprised eight 
uveitis specialists (seven ophthalmologists, one rheumatologist) who treated adults and / or 
children, and four paediatric ophthalmologists who managed childhood uveitis services. 
Response rates for rounds one and two were 100%.  
Of the 23 ophthalmologists invited to join second panel 19 (83%) replied. Five of these 
respondents described themselves as adult uveitis specialists, and declined to participate in 
the consensus exercise. Of the remaining 14 ophthalmologists, eight were uveitis specialists, 
and six paediatric ophthalmologists. Overall, 16/26 respondents (67%) submitted responses to 
all 44 items, and respondents abstained on a median of two items (range 0-8) which they felt 
were outside their area of expertise. One panel member changed their responses in round two, 
and one changed their responses in round four. Response rate for the last round was 92% 
(24/26). Consensus was reached on 23 of the 44 items.  
Initial investigations 
The majority of the Delphi group agreed with undertaking full blood count, liver function, 
urea and electrolyte, anti-nuclear antibody, human leucocyte antigen-B27, angiotensin 
converting enzyme, and erthrocyte sedimentation rate testing on children with chronic 
anterior uveitis without a diagnosis of JIA. However, the predefined threshold of 75% for 
group consensus was not reached for these items (table 1).. There was also absence of 
consensus on whether asymptomatic children should be referred for a paediatric 
rheumatology consultation), with respondents commenting that their investigations and 
referrals would be guided by the child’s history.  Group consensus was reached on the 
absence of an indication for complete HLA sequencing or Borrelia serology for these 
children (table 2).  
Management at presentation  
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Although the majority of the group agreed with the items on first line topical therapy for 
children with uveitis (67%, 16/24) and the use of systemic corticosteroids for children with 
sight threatening disease (14/24, 60%), group consensus was not achieved (table 1).  Eight 
respondents described a lower frequency of topical corticosteroid therapy (maximum four to 
six daily) than that suggested by published guidance (drops every one to two hours). Six 
respondents commented that a three month weaning period for oral steroids was too long for 
paediatric practice. 
There was consensus concerning the follow up of stable mild and moderate disease, with 
agreement that 0.5+ (Standardised Uveitis Nomenclature, SUN) anterior chamber cell activity 
should be seen again within 12 weeks, and 1+SUN or 2+SUN AC cells activity seen within 
six weeks. The group did not reach a consensus on the frequency of follow up for more 
severe activity [>2+ AC cells], inactive disease or those starting on a new steroid sparing 
systemic therapy.  
Definition and management of refractory disease  
The group reached consensus on the existing definitions of refractory disease (table 2). There 
was consensus on the use of methotrexate as a first line systemic immunosuppressive agent, 
with prescription supported by rheumatology clinical input, and monitoring shared by the 
child’s primary care giver (GP) or local paediatrician. Consensus was reached for 
adalimumab as a second line therapy for non JIA CAU (in addition to continuation of 
methotrexate), but not for the use of mycopenolate mofetil (MMF) or azathioprine as an 
alternative to methotrexate. An illustrative response to this itemstated that more evidence was 
needed on the relative benefit of adalimumab versus MMF as a second choice following 
methotrexate failure.  
Consensus was reached on the use of either another anti-TNF agent (ie Infliximab) or the use 
of an anti-IL-6 agent (eg, Tocilizumab) as a third line agent. However, only four of the 21 
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respondents declared a preference between the two classes of biologic immunomodulators. 
Whilst a consensus was not reached on the role of MMF or azathioprine in the management 
of non-JIA CAU refractory to Adalimumab, the majority of the group agreed with its use. 
There was consensus level disagreement with the use of ciclosporin for childhood CAU 
refractory to methotrexate and adalimumab used in combination. 
Systemic prednisolone therapy for the management of severe inflammation (chronic anterior 
uveitis with non-improving dense vitreous haze, macular oedema or SUN grade anterior cell 
activity of 4+ or worse) and pre-cataract surgery was agreed by consensus, but no consensus 
was reached on the use of  periocular corticosteroids for severe disease. The duration of 
disease remission acceptable prior to cataract surgery, suggested at three months, did not 
reach consensus level agreement. Two respondents suggested that 6-12 months of disease 
remission would be more appropriate, and 2 respondents suggesting that they would 
undertake surgery in children with persistent low grade activity (ie +0.5 SUN ACC) activity.  
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Table 1: Items on which group consensus was not reached 
Levels of evidence: Ia=More than 1 randomised controlled trial; 1b=1 RCT with narrow CI; II=1 
RCT, or 1 single centre cohort study with clear effect, or >1 multicentre observational study; III=Case 
control studies, retrospective case series, multi-centre consensus agreement, IV=Expert opinion 
 
Recommendation / Guideline 
Evidence 
Level 
Agreement 
Management at presentation      
Topical corticosteroid (prednisolone acetate 1 % or dexamethasone phosphate 0.1 %) 
used 1-2h for 1-3 days then wean, + cycloplegic  
III10,14 17/24: 71% 
Oral corticosteroid taper: tapering-off to ≤ 0.15 mg/kg within 4 weeks, and limited to 
3 months 
III14 15/23: 65% 
Investigations in absence of JIA      
FBC, ANA, HLA-B27, ACE, ESR, RhF, LFT, U&Es III15 16/24: 67% 
VDRL (Venereal disease research laboratory) test III15 9/23: 39% 
Rheumatology referral  IV15 14/24: 58% 
Follow up schedule for those on treatment  without co-morbidity     
At diagnosis - weekly ophthalmological visits III16  8/24: 33% 
At diagnosis – see within 3 weeks IV15 8/22: 36% 
In grades 3+ SUN or 4+  -  weekly visits until improvement III16 16/24: 67% 
In grades 3+ SUN or 4+  -  see within 3 weeks IV10 6/21: 29% 
Inactive - every 3 months III16 16/22: 73% 
Following commencement new DMARD – at 3 weeks & 3 months  III10,16 9/20: 45% 
Management of uveitis refractory to topical therapy      
Management of MTX transaminitis: withdraw if transaminase>3x normal upper limit 
until LFTs normalise 
III16 11/17: 65% 
Management of nJIA CAU refractory to MTX     
Mycophenolate mofetil 300mg/m2 BD to 600mg/m2 BD  III10 13/18: 72% 
Azathioprine 1mg/kg to 3mg/kg OD III15 7/18: 39% 
Definition of refractory to Adalimumab    
With confirmatory drug levels / ADA antibodies measured  III10,14,16 9/17: 53% 
Management of nJIA CAU refractory to MTX + Adalimumab     
Mycophenolate mofetil 300mg/m2 BD to 600mg/m2 BD  III14 14/19: 74% 
Azathioprine 1mg/kg to 3mg/kg OD III14 7/19: 37% 
Cyclosporine-A 3 mg/kg orally III14 6/19: 32% 
Management of non-improving dense vitreous haze / macular oedema / 4+ SUN 
whilst awaiting effect of maximal dose DMARD 
    
Consider orbital floor steroid injections  III14,15 10/22: 45% 
Consider subtenon steroid injection  III15,16 16/24: 67% 
Similar management considered for post cataract surgery MO  IV15 16/24: 67% 
Peri-cataract surgery prophylaxis     
Inflammation free for at least 12 weeks  III15 15/21: 71% 
Maintenance duration for DMARDS      
5 years  III15 8/24: 33% 
FBC: full blood count; ANA: anti-nuclear antibody; ACE: angiotensin converting enzyme; ESR: 
erythrocyte sedimentation ratio; RhF: rheumatoid factor; LFT: liver function tests; U&Es: urea and 
electrolytes 
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Table 2: Items on which group consensus was reached (≥75% group agreement with item, or ≤25% 
group disagreement with item)  
Item / extracted guideline 
Level of 
supportive  
evidence for 
item 
Agreement 
(n: %) 
Management at presentation      
Uveitis + comorbidity: as above plus systemic corticosteroids, oral prednisolone 
1–2 mg/kg/day with wean, or IV methylprednisolone 20–30 mg/kg/day for 1–3 
days 
III10,14,16 18/24: 75% 
Co-morbidity at presentation described as poor vision, hypotony, glaucoma, 
cataract, macular oedema, or dense vitreous body opacification 
III10,14,16 16/19: 84% 
Investigations in absence of JIA      
Complete HLA sequencing III15 3/23:13% 
Follow up schedule for those on treatment  without co-morbidity     
In grades 1+ SUN ACC or 2+ (two successive visits) - see within 6 weeks III16 18/21: 86% 
In grade 0.5+ SUN (two successive visits) – see within 3 months III16 18/22: 82% 
Definition of refractory (to topical tx)      
Sustained non-improvement of SUN+3 or greater for 1 month III10,14,16 20/22: 91% 
Requiring at least 3 drops daily for more than 3 months to maintain 1+SUN III10,16 21/23: 91% 
No improvement of 2 grades after 1 month  III10 20/22: 91% 
Worsening onset ocular morbidities after 3 months III10,14 20/21: 95% 
New onset ocular morbidities after 1 month III10,14,16 19/23: 83% 
Management of uveitis refractory to topical therapy      
Methotrexate  10–15 mg/m2 (or 0.3–0.6 mg/kg) PO or SC once weekly Ib10 18/22: 82% 
Commencement of MTX with support of rheumatologist or CNS III10 19/21: 90% 
Shared care with GP / local paediatrician to facilitate regular monitoring  III10 16/20: 80% 
Definition  of uveitis refractory to Methotrexate (MTX)     
No improvement of 2 grades, worsening, >2 flares / or flare sequelae after 3 
months  
III10 18/20: 90% 
Requiring at least 3 drops daily for more than 3 months to maintain 1+SUN III10,14 19/21: 90% 
Management of nonJIA CAU refractory to MTX     
Adalimumab 24mg/m2 SC every 2 weeks + MTX  III14 18/20: 90% 
Definition of refractory to Adalimumab      
Same as refractory to MTX  III10,15 21/21: 100% 
Management of nonJIA CAU refractory to MTX + Adalimumab     
OR MTX + another anti-TNF (Infliximab)  III14 15/16: 94% 
OR MTX + IL-6 (Tocilizumab)  III15 15/17: 88% 
Management of non-improving dense vitreous haze / macular oedema / 4+ 
SUN ACC whilst awaiting effect of maximal dose DMARD 
    
Systemic corticosteroids, oral prednisolone 1–2 mg/kg/day with wean, or IV 
methylprednisolone 20–30 mg/kg/day for 1–3 days 
III10,14 19/22: 86% 
Peri-cataract surgery prophylaxis     
Systemic corticosteroids (1 mg/kg 3-5 days pre, or 2 IV infusions of 500mg for 3 
days pre-op) 
III15 19/22: 86% 
Maintenance duration for DMARDS      
24 months (at grade 0 SUN)  III10,16 19/22: 86% 
HLA: Human Leukocyte Antigen; CAU: chronic anterior uveitis; PO: oral; SC: subcutaneous; IV: 
intravenous; SUN: standardised uveitis nomenclature; ACC: anterior chamber cells; TNF: tumour 
necrosis factor; IL-6: Interleukin-6; DMARD: Disease modifying anti-rheumatic drug; CNS: clinical 
nurse specialist 
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DISCUSSION 
Through the use of a modified Delphi process undertaken by a national network of specialists 
involved in the management of childhood uveitis, a lack of consensus on several aspects of 
disease management was identified. These aspects comprised management at presentation, 
initial investigation of non-JIA CAU, the regimen of systemic steroids for children with 
severe disease, and the choice and sequence of conventional immunosuppressant and biologic 
immunomodulator in those poorly responsive to the sequence of methotrexate followed by 
methotrexate plus adalimumab.  
The Delphi, and modified Delphi processes can be limited by the composition of the selected 
panel, the choice of items, and the features of the process itself, such as the absence of direct 
discussion within the panel.12 Panel specialists were distributed across the UK and consisted 
of both uveitis specialists managing children and paediatric ophthalmologists managing 
complex uveitis, representing the reality of national clinical practice. In the UK specialist 
centres for paediatric rheumatology are characterised by registered paediatric rheumatologists 
who are provided prescribing rights for some treatments. The managements of paediatric 
ocular inflammatory disease is a registered responsibility of these centres and trials of 
biologics for JIA-U has been limited to such centres. There is no such restriction on those 
prescribing conventional immunosuppressants to children with uveitis, and no obligation to 
refer all cases of paediatric uveitis to specialist ophthalmologists. 
The panel was split using designated specialist centre status as a marker of exposure to 
complex cases. Responses from these panel one members was shared with the second panel, 
which may have led to a ‘weighted’ response from panel two, encouraging convergence of 
opinion within the group, but also leading to response bias. It is however notable that most 
responses, and response rates, did not change from round to round, suggesting that dissenting 
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contributors did not disengage from the process, and that the anonymous structure of the 
Delphi encouraged independence of response.  
The selection of a 75% agreement level, in the absence of a ‘gold standard’ is in keeping with 
the literature12,18 and was agreed within the core group a priori. The items were pre-selected 
by the core group to ensure coverage of existing guidelines or treatment algorithms which 
were themselves evidence based and or derived through multi-centre consensus, and which 
covered the course of disease natural history from disease presentation to management of 
ocular complications.  
Two Delphi consensus exercises on CAU were completed and published whilst this study 
was underway. The Pan European Single Hub and Access point for paediatric Rheumatology 
in Europe (SHARE)19 initiative, and the  North American Childhood Arthritis and 
Rheumatology Research Alliance (CARRA)20 published consensus based recommendations 
on the management of JIA-U (SHARE) and both JIA-U and non-JIA-U CAU(CARRA). In 
contrast to this study, ophthalmologists were in the minority in both of these international 
groups. SHARE comprised nine rheumatologists and three ophthalmologists. CARRA 
comprised 10 rheumatologists and two ophthalmologists. One author of this study was a 
member of the SHARE consensus group [CE] and one [AR] a co-author.  There was 
considerable concordance in many areas between our findings and the SHARE and CARRA 
recommendation with regards to the importance of escalating to non-steroidal systemic 
treatment, the use of methotrexate as first line and anti-TNF biologic therapies as second line 
treatments. There was a significantly wider range of immunsuppressants suggested within 
CARRA as alternatives, reflecting international differences in drug availability and 
prescribing practices. In the UK funding for biologics other than adalimumab for refractory 
childhood uveitis requires an individualised application for funding unless there is systemic 
disease.21 This will have restricted the treatment decisions of the participants of this study.  
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There was disagreement between CARRA and SHARE on the definition of inactive disease, 
specifically whether persistent low grade activity (ie +0.5 SUN activity) is sufficient criteria 
for escalation of systemic therapy. Our expert panel was also unable to reach consensus on 
this. An agreed definition of a clinically significant level of minimum activity (ie one that 
does not  necessitates treatment escalation, and is not associated with an increased risk of 
relapse) remains elusive. There was, however, agreement within all three studies concerning 
definitions of poor treatment response.  
Chronic anterior uveitis is the commonest manifestation of childhood uveitis, and has been 
recognised by the European Medical Agency as sufficiently unique from adulthood disease to 
prevent extrapolation of data from adult uveitis trials.19,20 CAU in children with and without 
juvenile idiopathic arthritis may be sufficiently similar as to allow generalisability of the 
evidence base around JIA associated uveitis.19,20  A key difference, however, is the possibility 
of an underlying inflammatory diagnosis such as sarcoidosis in children with non JIA CAU. 
The elicitation of systemic features of disease can be a challenge for ophthalmologists, and it 
can be unclear as to whether children require paediatric or paediatric rheumatological input. 
The local prevalence of associated disorders can also guide the diagnostic algorithm. In the 
UK, the most common of these disorders are the juvenile idiopathic arthritides (including the 
HLA-B27 and enthesitis related spondyloarthropathies). To a lesser extent, other multi-
system inflammatory diseases may manifest as CAU.1 Up to 10% of children with Behcet’s 
disease present first with ocular features,22 and ocular involvement may be a more common 
feature of paediatric sarcoidosis than that seen in adult disease.23 Although we did not reach 
consensus on the investigation panel for asymptomatic children presenting with non-JIA 
associated CAU, ophthalmologists must remain aware that signs or symptoms of an 
underlying systemic disorder may not be apparent at the onset of uveitis.  
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Our findings are a future roadmap for essential research and the generation of the evidence 
base for improved future patient care.  Whilst we describe consensus on many aspects of 
management, we are unable to use all our findings as recommendations for clinical practice 
in childhood uveitis. In some cases there may be a justification in taking a patient led rather 
than protocol based approach, for example in the decision of follow up scheduling. Further 
evidence on other aspects of management are awaited from studies currently underway, such 
as the APTITUDE phase II trial of Tocilizumab in refractory JIA-U.24 However, at this time, 
the paucity of registered interventional trials suggests that an updated systematic review 
would not provide definitive management recommendations.  
Ophthalmological involvement in study design for international prospective cohort studies of 
children with these rare inflammatory systemic diseases, or ophthalmology-led registers of 
children with rare inflammatory eye disorders, would provide the population and data needed 
to develop and test diagnostic algorithms for those presenting with ocular signs in the 
apparent absence of systemic features. Multicentre clinical rare disease networks can also 
provide the specialist support needed for clinical decisions on this challenging patient group.  
POIG, and the disorder specific groups which sit within it, aims to provide an ophthalmology 
led multidisciplinary clinical network to enable the further research, both observational and 
interventional, which is needed for better outcomes for these rare, blinding childhood ocular 
inflammatory disorders.  
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